Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) have been assigned a consensus rating of “Moderate Buy” from the seven ratings firms that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $42.75.

A number of analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of Assembly Biosciences in a research report on Monday, May 4th. Guggenheim reaffirmed a “buy” rating and set a $43.00 price objective on shares of Assembly Biosciences in a research report on Thursday, May 28th. Wall Street Zen cut Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Monday, April 20th.

Assembly Biosciences Price Performance

NASDAQ:ASMB opened at $22.90 on Monday. The stock’s 50 day moving average price is $28.19 and its 200 day moving average price is $29.96. The company has a market capitalization of $363.88 million, a PE ratio of -208.16 and a beta of 1.08. Assembly Biosciences has a 52-week low of $15.54 and a 52-week high of $39.71.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.11. Assembly Biosciences had a negative return on equity of 4.21% and a negative net margin of 8.98%.The company had revenue of $8.21 million during the quarter, compared to analysts’ expectations of $9.27 million. As a group, sell-side analysts anticipate that Assembly Biosciences will post -0.79 EPS for the current fiscal year.

Institutional Trading of Assembly Biosciences

A number of hedge funds have recently added to or reduced their stakes in the stock. Farallon Capital Management LLC acquired a new stake in Assembly Biosciences during the 3rd quarter worth approximately $31,426,000. RA Capital Management L.P. acquired a new stake in Assembly Biosciences during the 3rd quarter worth approximately $26,122,000. Commodore Capital LP acquired a new stake in Assembly Biosciences during the 3rd quarter worth approximately $25,600,000. Janus Henderson Group PLC lifted its holdings in shares of Assembly Biosciences by 1.4% in the 1st quarter. Janus Henderson Group PLC now owns 849,309 shares of the biopharmaceutical company’s stock valued at $23,479,000 after buying an additional 11,384 shares during the period. Finally, Paradigm Biocapital Advisors LP acquired a new stake in shares of Assembly Biosciences in the 4th quarter valued at approximately $22,625,000. 19.92% of the stock is owned by institutional investors and hedge funds.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.